Research progress of drug-eluting beads in arterial chemoembolization for hepatocellular carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

JIN Hongyu ^1,2 ,  YUAN Chi ² , LIAO Mingheng ¹ , WANG Menghua ² , CAI Qiuyu ² , LIU Siyu ² ,  ZENG Yong ¹

1. Department of Liver Surgery & ?Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
2. West China School of Medicine, Sichuan University, Chengdu 610041, P. R. China;

Corresponding?author：

ZENG Yong, Email: zengyong@medmail.com.cn

Keywords：

hepatocellular carcinoma; transcatheter arterial chemoembolization; drug-eluting bead

DOI：

10.7507/1007-9424.201905100

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the research progress of four mainstream drug-eluting beads (DEB) in transcathete arterial chemoembolization (TACE) for hepatocellular carcinoma in recent years.Method Through retrieving relevant literatures at home and abroad, the physicochemical properties, pharmacokinetics, effectiveness, and safety of four mainstream DEBs were reviewed.Results The current mainstream DEBs on the market had the characteristics of high drug loading rate and sustained release of drugs, which could reduce the adverse reactions after the embolization to a certain extent. The safety and tolerance of patients receiving DEB-TACE were slightly higher than those receiving traditional TACE (c-TACE). There were no serious complications after the DEB-TACE, but the short-term and long-term efficacies between the two methods were not significantly different.Conclusions At present, most studies believe that the safety and tolerance of DEB are slightly higher than that of c-TACE, but whether the former is more effective than the latter is still controversial at home and abroad, and more high-quality multicenter randomized controlled trials are needed to confirm it.

Citation： JIN Hongyu, YUAN Chi, LIAO Mingheng, WANG Menghua, CAI Qiuyu, LIU Siyu, ZENG Yong. Research progress of drug-eluting beads in arterial chemoembolization for hepatocellular carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(2): 232-238. doi: 10.7507/1007-9424.201905100 Copy

1.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2.	中華人民共和國衛生和計劃生育委員會醫政醫管局. 原發性肝癌診療規范 (2017 年版). 傳染病信息, 2017, 16(7): 705-720.
3.	陳猛, 陳曉明. 2017 年載藥微球化療栓塞治療肝癌臨床研究進展. 循證醫學, 2018, 18(1): 26-28.
4.	Raoul JL, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev, 2019, 72: 28-36.
5.	Baur J, Ritter CO, Germer CT, et al. Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma. Hepat Med, 2016, 8: 69-74.
6.	Popovic P, Stabuc B, Jansa R, et al. Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control. Radiol Oncol, 2016, 50(4): 418-426.
7.	Liu YS, Lin CY, Chuang MT, et al. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. BMC Gastroenterol, 2018, 18(1): 124.
8.	陳圣群, 張岳林, 周官輝, 等. 國產載藥微球治療肝癌的近期療效分析. 心理醫生, 2018, 24(16): 82-83.
9.	樸相浩, 曾健瀅, 楊清峰, 等. Hepasphere?載藥微球栓塞治療中晚期肝細胞肝癌的安全性及療效分析. 現代腫瘤醫學, 2018, 26(11): 1732-1736.
10.	Melchiorre F, Patella F, Pescatori L, et al. DEB-TACE: a standard review. Future Oncol, 2018, 14(28): 2969-2984.
11.	Chang PY, Huang CC, Hung CH, et al. Multidisciplinary Taiwan consensus recommendations for the use of DEBDOX-TACE in hepatocellular carcinoma treatment. Liver cancer, 2018, 7(4): 312-322.
12.	Weng L, Tseng HJ, Rostamzadeh P, et al. In vitro comparative study of drug loading and delivery properties of bioresorbable microspheres and LC bead. J Mater Sci Mater Med, 2016, 27(12): 174.
13.	Lahti S, Ludwig JM, Xing M, et al. In vitro biologic efficacy of sunitinib drug-eluting beads on human colorectal and hepatocellular carcinoma—A pilot study. PLoS One, 2017, 12(4): e0174539.
14.	Hong K, Khwaja A, Liapi E, et al. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res, 2006, 12(8): 2563-2567.
15.	Liu DM, Kos S, Buczkowski A, et al. Optimization of doxorubicin loading for superabsorbent polymer microspheres: in vitro analysis. Cardiovasc Intervent Radiol, 2012, 35(2): 391-398.
16.	Sottani C, Poggi G, Quaretti P, et al. Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres. Anticancer Res, 2012, 32(5): 1769-1774.
17.	Zhou GH, Han J, Sun JH, et al. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres? beads in Chinese hepatocellular carcinoma patients. BMC Cancer, 2018, 18(1): 644.
18.	Zhang S, Huang C, Li Z, et al. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers. Drug delivery, 2017, 24(1): 1011-1017.
19.	Delicque J, Guiu B, Boulin M, et al. Liver chemoembolization of hepatocellular carcinoma using TANDEM. Future Oncol, 2018, 14(26): 2761-2772.
20.	Malagari K, Kiakidis T, Pomoni M, et al. Pharmacokinetics, safety, and efficacy of chemoembolization with doxorubicin-loaded tightly calibrated small microspheres in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol, 2016, 39(10): 1379-1391.
21.	de Baere T, Plotkin S, Yu R, et al. An in vitro evaluation of four types of drug-eluting microspheres loaded with doxorubicin. J Vasc Interv Radiol, 2016, 27(9): 1425-1431.
22.	Hagan A, Phillips GJ, Macfarlane WM, et al. Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies. Eur J Pharm Sci, 2017, 101: 22-30.
23.	Cho H, Cho Y, Yu SJ, et al. The efficacy and safety of doxorubicin-eluting bead transarterial chemoembolization over sorafenib for unresectable hepatocellular carcinoma with portal vein invasion. Hepatology, 2016, 64(1 Supplement 1): 637A.
24.	Lee M, Chung JW, Lee KH, et al. Korean multicenter registry of transcatheter arterial chemoembolization with drug-eluting embolic agents for nodular hepatocellular carcinomas: six-month outcome analysis. J Vasc Interv Radiol, 2017, 28(4): 502-512.
25.	Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION Ⅴ study. Cardiovasc Intervent Radiol, 2010, 33(1): 41-52.
26.	Malagari K, Pomoni M, Spyridopoulos TN, et al. Safety profile of sequential transcatheter chemoembolization with DC Bead^TM: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol, 2011, 34(4): 774-785.
27.	Monier A, Guiu B, Duran R, et al. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion. Eur Radiol, 2017, 27(4): 1431-1439.
28.	Duan F, Wang EQ, Lam MG, et al. Superselective Chemo-embolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion. Radiology, 2016, 278(2): 612-621.
29.	Zurstrassen CE, Gireli LPO, Tyng CJ, et al. Safety and efficacy of HepaSphere 50-100? μm in the treatment of hepatocellular carcinoma. Minim Invasive Ther Allied Technol, 2017, 26(4): 212-219.
30.	Xiang H, Long L, Yao Y, et al. CalliSpheres drug-eluting bead transcatheter arterial chemoembolization presents with better efficacy and equal safety compared to conventional TACE in treating patients with hepatocellular carcinoma. Technol Cancer Res Treat, 2019, 18: 1533033819830751.
31.	Wu B, Zhou J, Ling G, et al. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. World J Surg Oncol, 2018, 16(1): 69.
32.	周永祥, 張j景俊, 羅志剛, 等. CalliSpheres?載藥微球栓塞治療高齡肝癌患者的安全性分析. 廣東醫學, 2018, 39(10): 1561-1565.
33.	陳剛, 張鼎, 應亞草, 等. 國產載藥微球經動脈化療栓塞治療不可切除原發性肝癌的臨床研究. 浙江大學學報 (醫學版), 2017, 46(1): 44-51.
34.	Rahman FA, Naidu J, Ngiu CS, et al. Conventional versus doxorubicin-eluting beads transarterial chemoembolization for unresectable hepatocellular carcinoma: a tertiary medical centre experience in Malaysia. Asian Pac J Cancer Prev, 2016, 17(8): 4037-4041.
35.	Best J, Schotten C, Theysohn JM, et al. Novel implications in the treatment of hepatocellular carcinoma. Ann Gastroenterol, 2017, 30(1): 23-32.
36.	Nicolini D, Svegliati-Baroni G, Candelari R, et al. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol, 2013, 19(34): 5622-5632.
37.	Song MJ, Chun HJ, Song DS, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol, 2012, 57(6): 1244-1250.
38.	Sattler T, Bredt C, Surwald S, et al. Efficacy and safety of drug eluting bead TACE with microspheres. Anticancer Res, 2018, 38(2): 1025-1032.
39.	Lee S, Kim KM, Lee SJ, et al. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study. Acta Radiol, 2017, 58(2): 131-139.
40.	邱力戈, 梁若斯, 李勇, 等. HepaSphere?載藥微球與碘油化療栓塞大肝癌的不良反應比較. 中華介入放射學電子雜志, 2018, 6(2): 99-103.
41.	Kucukay F, Badem S, Karan A, et al. A single-center retrospective comparison of doxorubicin-loaded HepaSphere transarterial chemoembolization with conventional transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol, 2015, 26(11): 1622-1629.
42.	曹國洪, 王凱, 李佳琪, 等. CalliSpheres?載藥微球經動脈導管化療栓塞治療肝癌患者的有效性及安全性分析. 中國介入影像與治療學, 2018, 15(1): 42-46.
43.	Greco G, Cascella T, Facciorusso A, et al. Transarterial chemoembolization using 40 μm drug eluting beads for hepatocellular carcinoma. World J Radiol, 2017, 9(5): 245-252.
44.	Kloeckner R, Pitton MB, Dueber C, et al. Validation of clinical scoring systems ART and ABCR after transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol, 2017, 28(1): 94-102.
45.	Xing M, Webber G, Prajapati HJ, et al. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. J Gastroenterol Hepatol, 2015, 30(7): 1167-1174.
46.	Cucchetti A, Trevisani F, Cappelli A, et al. Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. Dig Liver Dis, 2016, 48(7): 798-805.
47.	Vadot L, Boulin M, Guiu B, et al. Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma. J Clin Pharm Ther, 2015, 40(1): 83-90.
48.	Pieper CC, Meyer C, Vollmar B, et al. Temporary arterial embolization of liver parenchyma with degradable starch microspheres (EmboCept^?S) in a swine model. Cardiovasc Intervent Radiol, 2015, 38(2): 435-441.
49.	Weng L, Rostamzadeh P, Nooryshokry N, et al. In vitro and in vivo evaluation of biodegradable embolic microspheres with tunable anticancer drug release. Acta Biomater, 2013, 9(6): 6823-6833.
50.	徐浩. 聚乙烯醇栓塞微球可載藥微球介入治療中晚期肝癌的臨床療效及安全性觀察. 實用癌癥雜志, 2017, 32(12): 1999-2001.
51.	劉墨, 黃伍奎, 劉登堯, 等. 國產海藻酸鈉載藥微球在原發性肝癌 TACE 治療中的安全性分析. 中國實用醫藥, 2017, 12(1): 37-39.
52.	Aliberti C, Carandina R, Sarti D, et al. Transarterial chemoembolization with DC Bead LUMI^TM radiopaque beads for primary liver cancer treatment: preliminary experience. Future Oncol, 2017, 13(25): 2243-2252.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. 中華人民共和國衛生和計劃生育委員會醫政醫管局. 原發性肝癌診療規范 (2017 年版). 傳染病信息, 2017, 16(7): 705-720.
3. 陳猛, 陳曉明. 2017 年載藥微球化療栓塞治療肝癌臨床研究進展. 循證醫學, 2018, 18(1): 26-28.
4. Raoul JL, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev, 2019, 72: 28-36.
5. Baur J, Ritter CO, Germer CT, et al. Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma. Hepat Med, 2016, 8: 69-74.
6. Popovic P, Stabuc B, Jansa R, et al. Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control. Radiol Oncol, 2016, 50(4): 418-426.
7. Liu YS, Lin CY, Chuang MT, et al. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. BMC Gastroenterol, 2018, 18(1): 124.
8. 陳圣群, 張岳林, 周官輝, 等. 國產載藥微球治療肝癌的近期療效分析. 心理醫生, 2018, 24(16): 82-83.
9. 樸相浩, 曾健瀅, 楊清峰, 等. Hepasphere?載藥微球栓塞治療中晚期肝細胞肝癌的安全性及療效分析. 現代腫瘤醫學, 2018, 26(11): 1732-1736.
10. Melchiorre F, Patella F, Pescatori L, et al. DEB-TACE: a standard review. Future Oncol, 2018, 14(28): 2969-2984.
11. Chang PY, Huang CC, Hung CH, et al. Multidisciplinary Taiwan consensus recommendations for the use of DEBDOX-TACE in hepatocellular carcinoma treatment. Liver cancer, 2018, 7(4): 312-322.
12. Weng L, Tseng HJ, Rostamzadeh P, et al. In vitro comparative study of drug loading and delivery properties of bioresorbable microspheres and LC bead. J Mater Sci Mater Med, 2016, 27(12): 174.
13. Lahti S, Ludwig JM, Xing M, et al. In vitro biologic efficacy of sunitinib drug-eluting beads on human colorectal and hepatocellular carcinoma—A pilot study. PLoS One, 2017, 12(4): e0174539.
14. Hong K, Khwaja A, Liapi E, et al. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res, 2006, 12(8): 2563-2567.
15. Liu DM, Kos S, Buczkowski A, et al. Optimization of doxorubicin loading for superabsorbent polymer microspheres: in vitro analysis. Cardiovasc Intervent Radiol, 2012, 35(2): 391-398.
16. Sottani C, Poggi G, Quaretti P, et al. Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres. Anticancer Res, 2012, 32(5): 1769-1774.
17. Zhou GH, Han J, Sun JH, et al. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres? beads in Chinese hepatocellular carcinoma patients. BMC Cancer, 2018, 18(1): 644.
18. Zhang S, Huang C, Li Z, et al. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers. Drug delivery, 2017, 24(1): 1011-1017.
19. Delicque J, Guiu B, Boulin M, et al. Liver chemoembolization of hepatocellular carcinoma using TANDEM. Future Oncol, 2018, 14(26): 2761-2772.
20. Malagari K, Kiakidis T, Pomoni M, et al. Pharmacokinetics, safety, and efficacy of chemoembolization with doxorubicin-loaded tightly calibrated small microspheres in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol, 2016, 39(10): 1379-1391.
21. de Baere T, Plotkin S, Yu R, et al. An in vitro evaluation of four types of drug-eluting microspheres loaded with doxorubicin. J Vasc Interv Radiol, 2016, 27(9): 1425-1431.
22. Hagan A, Phillips GJ, Macfarlane WM, et al. Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies. Eur J Pharm Sci, 2017, 101: 22-30.
23. Cho H, Cho Y, Yu SJ, et al. The efficacy and safety of doxorubicin-eluting bead transarterial chemoembolization over sorafenib for unresectable hepatocellular carcinoma with portal vein invasion. Hepatology, 2016, 64(1 Supplement 1): 637A.
24. Lee M, Chung JW, Lee KH, et al. Korean multicenter registry of transcatheter arterial chemoembolization with drug-eluting embolic agents for nodular hepatocellular carcinomas: six-month outcome analysis. J Vasc Interv Radiol, 2017, 28(4): 502-512.
25. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION Ⅴ study. Cardiovasc Intervent Radiol, 2010, 33(1): 41-52.
26. Malagari K, Pomoni M, Spyridopoulos TN, et al. Safety profile of sequential transcatheter chemoembolization with DC Bead^TM: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol, 2011, 34(4): 774-785.
27. Monier A, Guiu B, Duran R, et al. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion. Eur Radiol, 2017, 27(4): 1431-1439.
28. Duan F, Wang EQ, Lam MG, et al. Superselective Chemo-embolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion. Radiology, 2016, 278(2): 612-621.
29. Zurstrassen CE, Gireli LPO, Tyng CJ, et al. Safety and efficacy of HepaSphere 50-100? μm in the treatment of hepatocellular carcinoma. Minim Invasive Ther Allied Technol, 2017, 26(4): 212-219.
30. Xiang H, Long L, Yao Y, et al. CalliSpheres drug-eluting bead transcatheter arterial chemoembolization presents with better efficacy and equal safety compared to conventional TACE in treating patients with hepatocellular carcinoma. Technol Cancer Res Treat, 2019, 18: 1533033819830751.
31. Wu B, Zhou J, Ling G, et al. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. World J Surg Oncol, 2018, 16(1): 69.
32. 周永祥, 張j景俊, 羅志剛, 等. CalliSpheres?載藥微球栓塞治療高齡肝癌患者的安全性分析. 廣東醫學, 2018, 39(10): 1561-1565.
33. 陳剛, 張鼎, 應亞草, 等. 國產載藥微球經動脈化療栓塞治療不可切除原發性肝癌的臨床研究. 浙江大學學報 (醫學版), 2017, 46(1): 44-51.
34. Rahman FA, Naidu J, Ngiu CS, et al. Conventional versus doxorubicin-eluting beads transarterial chemoembolization for unresectable hepatocellular carcinoma: a tertiary medical centre experience in Malaysia. Asian Pac J Cancer Prev, 2016, 17(8): 4037-4041.
35. Best J, Schotten C, Theysohn JM, et al. Novel implications in the treatment of hepatocellular carcinoma. Ann Gastroenterol, 2017, 30(1): 23-32.
36. Nicolini D, Svegliati-Baroni G, Candelari R, et al. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol, 2013, 19(34): 5622-5632.
37. Song MJ, Chun HJ, Song DS, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol, 2012, 57(6): 1244-1250.
38. Sattler T, Bredt C, Surwald S, et al. Efficacy and safety of drug eluting bead TACE with microspheres. Anticancer Res, 2018, 38(2): 1025-1032.
39. Lee S, Kim KM, Lee SJ, et al. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study. Acta Radiol, 2017, 58(2): 131-139.
40. 邱力戈, 梁若斯, 李勇, 等. HepaSphere?載藥微球與碘油化療栓塞大肝癌的不良反應比較. 中華介入放射學電子雜志, 2018, 6(2): 99-103.
41. Kucukay F, Badem S, Karan A, et al. A single-center retrospective comparison of doxorubicin-loaded HepaSphere transarterial chemoembolization with conventional transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol, 2015, 26(11): 1622-1629.
42. 曹國洪, 王凱, 李佳琪, 等. CalliSpheres?載藥微球經動脈導管化療栓塞治療肝癌患者的有效性及安全性分析. 中國介入影像與治療學, 2018, 15(1): 42-46.
43. Greco G, Cascella T, Facciorusso A, et al. Transarterial chemoembolization using 40 μm drug eluting beads for hepatocellular carcinoma. World J Radiol, 2017, 9(5): 245-252.
44. Kloeckner R, Pitton MB, Dueber C, et al. Validation of clinical scoring systems ART and ABCR after transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol, 2017, 28(1): 94-102.
45. Xing M, Webber G, Prajapati HJ, et al. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. J Gastroenterol Hepatol, 2015, 30(7): 1167-1174.
46. Cucchetti A, Trevisani F, Cappelli A, et al. Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. Dig Liver Dis, 2016, 48(7): 798-805.
47. Vadot L, Boulin M, Guiu B, et al. Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma. J Clin Pharm Ther, 2015, 40(1): 83-90.
48. Pieper CC, Meyer C, Vollmar B, et al. Temporary arterial embolization of liver parenchyma with degradable starch microspheres (EmboCept^?S) in a swine model. Cardiovasc Intervent Radiol, 2015, 38(2): 435-441.
49. Weng L, Rostamzadeh P, Nooryshokry N, et al. In vitro and in vivo evaluation of biodegradable embolic microspheres with tunable anticancer drug release. Acta Biomater, 2013, 9(6): 6823-6833.
50. 徐浩. 聚乙烯醇栓塞微球可載藥微球介入治療中晚期肝癌的臨床療效及安全性觀察. 實用癌癥雜志, 2017, 32(12): 1999-2001.
51. 劉墨, 黃伍奎, 劉登堯, 等. 國產海藻酸鈉載藥微球在原發性肝癌 TACE 治療中的安全性分析. 中國實用醫藥, 2017, 12(1): 37-39.
52. Aliberti C, Carandina R, Sarti D, et al. Transarterial chemoembolization with DC Bead LUMI^TM radiopaque beads for primary liver cancer treatment: preliminary experience. Future Oncol, 2017, 13(25): 2243-2252.

Previous Article
完全經皮二尖瓣植入和主動脈瓣 Valve-in-valve 植入術一例
Next Article
先天性主動脈-肺動脈間隔缺損伴右冠狀動脈異常起源于肺動脈一例

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research progress of drug-eluting beads in arterial chemoembolization for hepatocellular carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content